Use of antipsychotic polypharmacy among patients with schizophrenia and risk of death

被引：0
|
作者：
Gasse, Christiane [1 ]
Baandrup, Lone [2 ]
Nordentoft, Merete [4 ]
Glenthoj, Birte Y. [2 ]
Lublin, Henrik [2 ]
Jensen, Vibeke Dahl [3 ]
Thomsen, Lars Krogsgaard [3 ]
Poulsen, Jan [3 ]
Mortensen, Preben B. [1 ]
机构：
[1] Univ Aarhus, Natl Ctr Register Based Res, Aarhus, Denmark
[2] Copenhagen Univ Hosp, Fac Hlth Sci, Ctr Neuropsychiat Schizophrenia Res, Glostrup, Denmark
[3] Danish Med Agcy, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Dept Psychiat, Bispebjerg, Denmark
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
465
引用
收藏
页码：S204 / S205
页数：2
相关论文
共 50 条
  • [41] Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
    Tiihonen, Jari
    Taipale, Heidi
    Mehtala, Juha
    Vattulainen, Pia
    Correll, Christoph U.
    Tanskanen, Antti
    JAMA PSYCHIATRY, 2019, 76 (05) : 499 - 507
  • [42] Effects of switching polypharmacy into antipsychotic monotherapy using perospirone in patients with schizophrenia
    Shimizu, Hideaki
    Hokoishi, Kazuhiko
    Fukuhara, Ryuji
    Ishikawa, Tomohisa
    Ikeda, Manabu
    Tanabe, Hirotaka
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (05) : A5 - A5
  • [43] THE FREQUENCY OF ANTIPSYCHOTIC POLYPHARMACY IN "HIGH-UTILIZING'' PATIENTS WITH SCHIZOPHRENIA IN GERMANY
    Janssen, Birgit
    Schmidt-Kraepelin, C.
    Puschner, B.
    Gaebel, Wolfgang
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 306 - 307
  • [44] Antipsychotic polypharmacy in treatment-resistant schizophrenia
    Dugan, DJ
    Vertrees, JE
    Saklad, SR
    Richards, AM
    Ereshefsky, L
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 278 - 278
  • [45] Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
    Yasui-Furukori, Norio
    Shimoda, Kazutaka
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (03) : 208 - 210
  • [46] Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
    Lahteenvuo, Markku
    Tiihonen, Jari
    DRUGS, 2021, 81 (11) : 1273 - 1284
  • [47] Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale
    Azorin, Jean-Michel
    Simon, Nicolas
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (12) : 1175 - 1186
  • [48] Critical review of antipsychotic polypharmacy in the treatment of schizophrenia
    Fleischhacker, W. Wolfgang
    Uchida, Hiroyuki
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 (07): : 1083 - 1093
  • [49] Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
    Markku Lähteenvuo
    Jari Tiihonen
    Drugs, 2021, 81 : 1273 - 1284
  • [50] Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan
    Qiu, Hong
    He, Yong
    Zhang, Yongjing
    He, Minfu
    Liu, Jin
    Chi, Rui
    Si, Tianmei
    Wang, Huaning
    Dong, Wentian
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 (12): : 1202 - 1212
12345